These PD-1/PD-L1 inhibitory antibodies have been used as frontline treatment for various types of cancers, such as metastatic melanoma, non-small cell lung cancer (NSCLC), renal cell carcinoma (RCCs), and bladder or urothelial cancer [64,65]. This evidence concerns the gene CD274 and non-small cell lung carcinoma.